News | March 16, 2008

Study Targets Temperature Within 30 Minutes After Heart Attack

March 11, 2008 – The FDA cleared an investigational device exemption (IDE) application from Life Recovery Systems to use the ThermoSuit noninvasive cooling system to investigate rapid hypothermia treatment in combination with primary angioplasty to treat heart attacks.

Previous clinical data suggested early and rapid cooling before reperfusion therapy with primary angioplasty may potentially reduce infarct size post reperfusion. Life Recovery Systems’ said its objective is to rapidly cool the patient to target temperature in less than 30 minutes in preparation for PCI and without exceeding the AHA/ACC guidelines for door-to-balloon time.

The study will enroll up to twenty patients at two institutions who present within six hours of symptom onset and require PCI to restore blood flow to the heart. Patients will receive hypothermia with the Life Recovery Systems ThermoSuit noninvasive cooling system. Cooling will be performed in the emergency room within 60 minutes of arrival and cooling time is to be less than 30 minutes to avoid prolonging door-to-balloon time beyond 90 minutes.

The study is co-chaired by Paul McMullan, M.D., and Christopher White, M.D., chairman of cardiology for Ochsner Health System in New Orleans, LA.

In the Cool MI I trial, a subset of patients with anterior infarctions and whose temperature at the time of reperfusion was below 35 degrees C (26 percent of all anterior MI’s in the cooled group) had a significantly smaller infarction (9.3 percent of the left ventricular mass in the cooled population vs. 18.2 percent in the control group p=0.05) than the control group, indicated Dr. McMullan.

The goal of this pilot study is to confirm the feasibility and efficacy of external thin film liquid cooling to achieve target temperature within 30 minutes or less, and to demonstrate ease of maintenance of target temperature for three hours following removal of the patient from ThermoSuit. Primary safety endpoints data will also be collected. If this trial successfully achieves it its endpoints, a larger prospective randomized trial will be conducted.

For more information: www.life-recovery.com and www.ochsner.org

Related Content

therapeutic hypothermia, children, cardiac arrest, treatment, temperature
Feature | May 04, 2015
A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain...
News | December 11, 2014
Researchers at Okayama University in collaboration with several medical centers in Japan have demonstrated the safety...
Feature | September 19, 2014
September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-...
Technology | July 10, 2014
July 10, 2014 — Life Recovery Systems announced the U.S. Food and Drug Administration (FDA) has approved two...
therapeutic hypothermia, Philips InnerCool

The Philips InnerCool RTx system was used in the CHILL-MI study for use in STEMI patients.

Feature | February 03, 2014 | Dave Fornell
Use of therapeutic hypothermia is used to prevent neurological damage in patients who suffer sudden cardiac arrest (SCA...
BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
News | January 22, 2014
BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill...
rhinochill, RhinoChill, benechill, BeneChill

RhinoChill IntraNasal Cooling System

News | December 03, 2013
With the benefits of conventional strategies for therapeutic hypothermia following cardiac arrest being called in to ...
therapeutic hypothermia temperature management cath lab clinical trial study
Feature | November 01, 2013
clinical trial shows that rapidly cooling...
News | October 01, 2013
The Cardiovascular Research Foundation (CRF) announced the late breaking trials and first report investigations that...
News | August 06, 2013
Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study...
Overlay Init